CD274 and non-small cell lung carcinoma: In NSCLC cells with EGFR mutations, activated EGFR can upregulate PD-L1 expression through either the IL-6/JAK/STAT3 signaling pathway or the p-ERK1/2/p-c-Jun pathway[78,79].